Drug intelligence / Profile preview

HUBPE004.1

Development stage: Preclinical
Lead developer: Ambiotech
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

HUBPE004.1 is an exosome-based therapy being developed by AM Biotech for the treatment of premature ovarian failure, menopausal symptoms, and intimate area care. The product is generated using the company's proprietary Biochemical Pulse Exosome Drug Development Platform, which aims to produce high-potency exosomes with specific therapeutic properties. Currently in the preclinical stage, HUBPE004.1 represents a regenerative medicine approach to addressing gynecological and menopausal health issues by leveraging the signaling and reparative capabilities of extracellular vesicles.

Beyond the preview

Go deeper on HUBPE004.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUBPE004.1.

Explore the full profile